Advertisement

Topics

BMS' Opdivo Flounders in Phase III Trial for Small Cell Lung Cancer

20:00 EDT 11 Oct 2018 | BioSpace

Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo failed to meet endpoints as a treatment option for small cell lung cancer (SCLC) patients who relapsed following platinum-based chemotherapy.

Original Article: BMS' Opdivo Flounders in Phase III Trial for Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "BMS' Opdivo Flounders in Phase III Trial for Small Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...